Group items tagged

The Virtual Cancer Center Director Award (VCCDA) mechanism is a unique, interactive virtual cancer center (VCC) focused on bringing together two established investigators (Director and Deputy Director) and up to nine early career investigators (Scholars) to interrogate the commonalities of cancer. Candidates for Scholars will apply to a separate funding opportunity (W81XWH-20-PRCRP-CDA). The Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with the Scholars' Career Guides, assess the progress of the Scholars, promote the cross pollination of different cancer disciplines, and facilitate communication and collaboration amongst all of the VCC members. The overarching goal of the VCC is to develop successful, highly productive Scholars in a collaborative research and career developmental environment. The VCC will provide intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The VCC will give Scholars opportunities to operate in a collegial, highly dynamic, and cutting edge center to lead cancer research to a new frontier. It is the intention that through the VCC, collaborations will foster new growth in different cancers and spur an integrated cancer center to ensure the research advancements across different cancers.

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC

Through this Funding Opportunity Announcement (FOA), the NCI invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors. This RFA supports research that requires the creation of a new prospective cohort study of cancer survivors that addresses a gap in knowledge pertaining to the health of cancer survivors. Proposals must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or other understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and include information from the following five domains: 1) disease characteristics (e.g., type, stage), 2) individual survivor characteristics (e.g., comorbidities, SES, social connections, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity) and 5) quality of life outcomes (health related quality of life). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3 Planning-Exploratory Phase focused on recruitment and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 will be proposed by the PI, with approval by NCI, and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated so that all aims will be completed in the UH3 phase.

Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.

Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The current Program Announcement discusses the Breakthrough Award Level 3. Funding Levels 1, 2, and 4 are available under other Program Announcements (W81XWH-20-BCRP- BTA12-2 for Levels 1 and 2 and W81XWH-20-BCRP-BTA4-2 for Level 4). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award Program Announcements before submitting the pre- application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

The Fusion Energy Sciences (FES) program of the Office of Science (SC) and the Defense Program (DP) of the National Nuclear Security Administration (NNSA), both of the U.S. Department of Energy (DOE), jointly announce their interests in receiving grant applications for new awards and grant renewals for research in the SC-NNSA Joint Program in High-Energy-Density (HED) laboratory plasmas. All individuals or groups planning to submit applications for new or renewal funding in Fiscal Year 2018 should submit in response to this Funding Opportunity Announcement (FOA). The specific areas of interest are: 1. HED Hydrodynamics 2. Radiation-Dominated Dynamics and Material Properties 3. Magnetized HED Plasma Physics 4. Nonlinear Optics of Plasmas and Laser-Plasma Interactions 5. Relativistic HED Plasmas and Intense Beam Physics 6. Warm Dense Matter 7. High-Z, Multiply Ionized HED Atomic Physics 8. Diagnostics for HED Laboratory Plasmas More specific information on each area of interest is outlined in the general and program specific supplementary information provided.

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research provides funding for multiple efforts, including funding for innovative research pilot studies, scholar grants to up-and-coming investigators to encourage careers in ovarian cancer research, conducting public early detection screening for ovarian cancer, and producing nationally and internationally attended research symposia on ovarian cancer. To that end, the center is accepting applications for pilot study projects in ovarian cancer research. Through the center's Pilot Study Program, approximately ten one-year $75,000 grants will be awarded to support investigator-initiated projects in all areas of ovarian cancer research. Projects designed to analyze data from already funded clinical trials also will be considered. Priority will be given to proposals that are innovative, multidisciplinary, likely to lead to submission of grant applications for independently funded investigations, and have translational research potential.

Alex's Lemonade Stand Foundation is dedicated to raising money and awareness of the causes of childhood cancer. The foundation emerged from the front-yard lemonade stand of four-year-old Alexandra "Alex" Scott, who while fighting cancer herself wanted to raise money to find cures for all children with cancer. Her spirit and determination was inspirational, and by her untimely death at the age of 8, Alex had helped raise $1 million. Today, ALSF is one of the leading funders of pediatric cancer research in the United States and Canada. To advance this mission, ALSF is inviting applications for is Young Investigator Grants program.  Through the program, a grant of up to $150,000 over three years will be awarded in support of research scientists in the early stages of their careers such as postdoctoral or clinical fellows with a commitment to pediatric cancer investigation.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The Government reserves the right to fund an application at a lower funding level. Sectioned out through different award types.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R21 applications for exploratory/developmental research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

The Conquer Cancer Foundation was founded by cancer doctors at the American Society of Clinical Oncology to support dramatic advances in the prevention, treatment, and cures of all types of cancer. To that end, CCF is accepting applications for its Global Oncology Young Investigator Award. Through the program, a single grant of up to $50,000 will be awarded to an early-career investigator in support of global oncology research. "Global oncology" as defined by the foundation implies an approach to the practice of oncology that acknowledges the reality of limited resources in most parts of the world. Projects therefore need to be a research exercise - identifying training models, researching their outcomes, analyzing the outcomes of those models to select the most effective curriculum, and/or researching the cost of creating sustainable models where they do not exist.

The Rivkin Center is announcing funds for Pilot Study Awards to be allocated based on scientific merit. Pilot Study Awards support investigator-initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered. The two-year awards will provide a total of $75,000 in funding, with the possibility of an additional $25,000 awarded in year two, upon evaluation of year one progress, contingent on availability of funds.

Join BioOhio and the Columbus chapter of the Healthcare Businesswomen's Association (HBA) for a FREE online event - our second Diversity in Bioscience & Healthcare event of 2020, on August 20 at 5 pm. The engaging discussion focuses on the importance of supporting STEM programming at an early age within under-represented communities to encourage careers within the science and healthcare industries. Our special guests include: Frederic Bertley, Ph.D., President & CEO, COSI Kirsten M. Ellenbogen, Ph.D., President & CEO, Great Lakes Science Center Kelly Lewis, Bioscience Technologies Program Instructor, Eastland-Fairfield Career and Technical Schools Lead by the talented Brooke Cartus, Director of Business Development and Senior Facilitator, ImprovEdge! Featuring networking opportunities during the event! This discussion will be held via Zoom. Login instructions are included in your registration confirmation email and reminder emails sent before the event. BioOhio and the Healthcare Business Women's Association (HBA) support all efforts to increase diversity and inclusion within the bioscience and healthcare industries and invite you to join us for our next discussion, Overcoming Obstacles in the Workplace: Making Work Accessible on November 14th, 2020. This event is brought to you by BioOhio in partnership with the Columbus chapter of the Healthcare Businesswomen's Association (HBA) and is made possible by the generous support of BioOhio members AtriCure and BIO.

LIVESTRONG Cancer Institutes' mission: To rethink the full range of cancer care, from prevention to diagnosis, treatment, survivorship and end-of-life care - all with a focus on the patient's needs, values and preferences. Projects and organizations funded must also directly support the LIVESTRONG mission and the mission of the LIVESTRONG Cancer Institutes and should not be at odds with either mission.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee. Applications will be evaluated based on the following:  - The applicant's capacity to conduct bold, exceptionally creative research. - The novelty and creativity of the proposed research. Incremental research will not be funded. - The potential of the proposed research to lead to advances that will significantly impact the prevention, diagnosis, treatment or basic understanding of cancer. - The applicant's lack of resources to pursue the proposed research.

f you are a researcher or research administrator new to working with the NIH application and award process and want to learn more, or just want to get up-to-date on the latest NIH policy updates and grants process information, this seminar, which will be held June 26-28 at the Renaissance Baltimore Harborplace Hotel, is for you. More than 30 NIH and HHS experts will gather to present on program funding at this event. The seminar offers unique and valuable opportunities for anyone interested in the latest information about the application process, navigating the peer review process, and managing an award. Meet one-on-one with NIH grants, program, and review officials, as well as NIH and HHS policy officers…and network with hundreds of attendees from around the world.

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure, or treatment of primary brain tumors/brain cancer. The annual award provides up to $600,000 in funding over a four-year period. Over that time, recipients also receive additional support from the foundation through its network of scientists in the field and an annual alumni conference.